325 related articles for article (PubMed ID: 15367886)
1. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma.
Niedergethmann M; Wostbrock B; Sturm JW; Willeke F; Post S; Hildenbrand R
Pancreas; 2004 Oct; 29(3):204-11. PubMed ID: 15367886
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection.
Niedergethmann M; Hildenbrand R; Wolf G; Verbeke CS; Richter A; Post S
Int J Pancreatol; 2000 Aug; 28(1):31-9. PubMed ID: 11185708
[TBL] [Abstract][Full Text] [Related]
3. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.
Niedergethmann M; Hildenbrand R; Wostbrock B; Hartel M; Sturm JW; Richter A; Post S
Pancreas; 2002 Aug; 25(2):122-9. PubMed ID: 12142733
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.
Thomssen C; Schmitt M; Goretzki L; Oppelt P; Pache L; Dettmar P; Jänicke F; Graeff H
Clin Cancer Res; 1995 Jul; 1(7):741-6. PubMed ID: 9816040
[TBL] [Abstract][Full Text] [Related]
5. Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers.
Jain M; Bakhshi S; Shukla AA; Chauhan SS
Ann Hematol; 2010 Dec; 89(12):1223-32. PubMed ID: 20567828
[TBL] [Abstract][Full Text] [Related]
6. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis.
Lah TT; Kalman E; Najjar D; Gorodetsky E; Brennan P; Somers R; Daskal I
Hum Pathol; 2000 Feb; 31(2):149-60. PubMed ID: 10685628
[TBL] [Abstract][Full Text] [Related]
7. Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo.
Menzel K; Hausmann M; Obermeier F; Schreiter K; Dunger N; Bataille F; Falk W; Scholmerich J; Herfarth H; Rogler G
Clin Exp Immunol; 2006 Oct; 146(1):169-80. PubMed ID: 16968411
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors.
Kawasaki G; Kato Y; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Apr; 93(4):446-54. PubMed ID: 12029284
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer.
Zhang W; Wang S; Wang Q; Yang Z; Pan Z; Li L
Oncol Rep; 2014 Mar; 31(3):1334-42. PubMed ID: 24402045
[TBL] [Abstract][Full Text] [Related]
10. Expression and Clinical Implications of Cysteine Cathepsins in Gallbladder Carcinoma.
Mehra S; Panwar R; Thakur B; Yadav R; Kumar M; Singh R; Dash NR; Sahni P; Chauhan SS
Front Oncol; 2019; 9():1239. PubMed ID: 31824841
[No Abstract] [Full Text] [Related]
11. Clinical significance of cathepsin L and cathepsin B in dilated cardiomyopathy.
Mehra S; Kumar M; Manchanda M; Singh R; Thakur B; Rani N; Arava S; Narang R; Arya DS; Chauhan SS
Mol Cell Biochem; 2017 Apr; 428(1-2):139-147. PubMed ID: 28074340
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I
Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
[TBL] [Abstract][Full Text] [Related]
13. Double deficiency of cathepsins B and L results in massive secretome alterations and suggests a degradative cathepsin-MMP axis.
Tholen S; Biniossek ML; Gansz M; Ahrens TD; Schlimpert M; Kizhakkedathu JN; Reinheckel T; Schilling O
Cell Mol Life Sci; 2014 Mar; 71(5):899-916. PubMed ID: 23811845
[TBL] [Abstract][Full Text] [Related]
14. Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B/L double-deficient mice.
Sevenich L; Pennacchio LA; Peters C; Reinheckel T
Biol Chem; 2006 Jul; 387(7):885-91. PubMed ID: 16913838
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer cells express cathepsins B and L but not cathepsins K or H.
Ishibashi O; Mori Y; Kurokawa T; Kumegawa M
Cancer Biochem Biophys; 1999 Jul; 17(1-2):69-78. PubMed ID: 10738903
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
Harbeck N; Alt U; Berger U; Kates R; Krüger A; Thomssen C; Jänicke F; Graeff H; Schmitt M
Int J Biol Markers; 2000; 15(1):79-83. PubMed ID: 10763146
[TBL] [Abstract][Full Text] [Related]
18. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer.
Kahlert C; Bergmann F; Beck J; Welsch T; Mogler C; Herpel E; Dutta S; Niemietz T; Koch M; Weitz J
BMC Cancer; 2011 Jun; 11():275. PubMed ID: 21708005
[TBL] [Abstract][Full Text] [Related]
19. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
20. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
